UBS Warburg Cuts Kos Pharmaceuticals to 'Neutral'

Analyst C.J. Sylvester says the drug maker's stock is fully valued after a recent run-up

UBS Warburg downgraded Kos Pharmaceuticals (KOSP ) to neutral from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.